Cito Diagnostics

Executive Summary

Cito Diagnostics, founded in 2018 and headquartered in Leiden, Netherlands, is pioneering a 'Diagnostics as a Service' model that brings rapid, independent point-of-care testing to users outside traditional central laboratories. The company integrates point-of-care machines, rapid tests, and a proprietary software platform called Lab in App, which guides testing workflows and digitizes results for immediate actionability. By enabling safe, efficient, and decentralized diagnostics, Cito aims to reduce turnaround times and improve access to critical health information in settings such as primary care clinics, pharmacies, and remote healthcare facilities. While the company is still in a private, early-stage phase with no disclosed funding or valuation, its focus on the growing point-of-care diagnostics market positions it to address key challenges in healthcare delivery, particularly in underserved or time-sensitive scenarios. Cito Diagnostics differentiates itself through a holistic service approach rather than a single device, potentially lowering barriers for adoption. However, as a relatively young company with limited public data on commercial traction, its near-term viability depends on securing strategic partnerships, regulatory clearances, and funding to scale operations. The diagnostics market is competitive, but Cito's integrated platform could capture niche opportunities in decentralized testing. With no disclosed revenue or pipeline specifics, the company's progress should be monitored for key milestones that demonstrate market validation and execution capability.

Upcoming Catalysts (preview)

• Q3 2026Partnership with major pharmacy chain or primary care network for Lab in App deployment40% success
• Q4 2026CE marking of a novel rapid test for respiratory or infectious disease50% success
• Q2 2026Series A funding round with lead institutional investor45% success